Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.

[1]  M Mazumdar,et al.  Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Gleave,et al.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. , 1992, Cancer research.

[4]  J. Veldscholte,et al.  Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. , 1992, Biochemistry.

[5]  J. Miller,et al.  The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.

[6]  V. Jordan,et al.  Hormonal strategies for breast cancer: a new focus on the estrogen receptor as a therapeutic target. , 1992, Seminars in oncology.

[7]  D. Tindall,et al.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. , 1991, Cancer research.

[8]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[9]  J. Oesterling,et al.  Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? , 1991, The Journal of urology.

[10]  W. Linehan,et al.  Effect of suramin on human prostate cancer cells in vitro. , 1991, The Journal of urology.

[11]  J. Veldscholte,et al.  Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[13]  N. Geller,et al.  Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Tindall,et al.  Molecular cloning of androgen receptors from divergent species with a polymerase chain reaction technique: complete cDNA sequence of the mouse androgen receptor and isolation of androgen receptor cDNA probes from dog, guinea pig and clawed frog. , 1990, Biochemical and biophysical research communications.

[15]  N. Olea,et al.  The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. , 1990, Endocrinology.

[16]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[17]  G. Chodak,et al.  Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma. , 1989, Urology.

[18]  V. Jordan,et al.  Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.

[19]  J. Drago,et al.  Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial. , 1985, Anticancer research.

[20]  C. Eggers,et al.  CANCER OF THE BREAST , 1941, Annals of surgery.